The University of Puerto Rico (UPR) is a state-funded institution that was established in 1903 as Puerto Rico’s first public institution of higher education, is host of the Puerto Rico IDeA Network Biomedical Research Excellence (PRINBRE). PRINBRE is a program inspired by the National Institutes of Health Institutional Developmental Awards: IDeA Networks of Biomedical Research Excellence (INBRE). Thus, PRINBRE is a program whose efforts are to promote the continued development of biomedical research infrastructure in Puerto Rico. Such continued development is achieved through the implementation of a strengthened and cohesive structure and integration of common scientific and educational interests, collaborations, and a newly created Mentoring Initiative.

PRINBRE will advance the development, coordination and sharing of research resources and expertise and will expand research opportunities for the biomedical research community in Puerto Rico, with emphasis on the Primarily Undergraduate Institutions (PUIs) of the Alliance. In addition PRINBRE impact on Puerto Rico’s Workforce and Economy focuses on development and enhancing the research capacity in science and biotechnology in Puerto Rico.

The main goals of the Puerto Rico IDeA Network Biomedical Research Excellence (PRINBRE) proposal are to: (1) enhance and strengthen the scientific infrastructure and research competitiveness of the Commonwealth in three specific research areas deemed to be key to advance Puerto Rico’s biomedical and behavioral research capacity; (2) elevate the productivity, competitiveness, and number of human resources needed to attract established investigators in those research areas; and (3) promote the development of research skills of talented junior investigators and gifted students. The Alliance created  counts with three distinct institutional types, namely Mentoring, Primarily Undergraduate Institutions (PUIs), and Outreach Institutions.

The Scientific Cluster Areas to be enhanced and strengthen were selected by the PRINBRE Steering Committee (described below) after consensus of all participating institutions, and these will remain similar as during Phase II, namely Neuroscience, Drug Development, and Molecular Medicine.